DIFF Biotech's Innovative Nasal Spray Influenza Vaccine Receives Clinical Trial Approval, Introducing a New Attenuation Pathway

The IND application for the clinical trial of the independently developed nasal spray influenza attenuated live vaccine has been officially accepted

Dr. Jiasheng Song from DIFF Biotech Invited to Attend the 2024 U.S.-China Collaborative Innovation Project Promotion Conference

DIFF Biotech (Hefei) Celebrates Grand Opening, Marking a New Chapter of Growth

DIFF Biotech Expands Global Presence with Launch of Singapore Subsidiary